Immunoglobulin Market (PI & CIDP ) Analysis and Forecasts to 2019...
“Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease” is...(PRWeb May 27, 2013)Read the full story at http://www.prweb.com/releases/immunoglobulin-market/pi-cidp-analysis-2019/prweb10772086.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 29, 2013 Category: Pharmaceuticals Source Type: news
CHMP recommends approval of Privigen® (human normal immunoglobulin) for chronic inflammatory demyelinating polyneuropathy
Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended a variation to the terms of the marketing authorisation for Privigen® (human normal immunoglobulin). The CHMP recommends the adoption of a new indication: the treatment of adults, and children and adolescents (0-18 years) with chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP.
Detailed recommendations for the use of this product will be described in ...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news
